Amylase Reagent 12ml Liquid Stable
Pack Sizes Available
Product Description
Technical Specifications
- Brand / Manufacturer: Infinite — Accurex Biomedical Pvt Ltd, Mumbai, India; India's first biochemical reagent manufacturing company; CDSCO registered IVD diagnostic reagent; Infinite brand — full clinical chemistry parameter range
- Method and Principle: CNPG3 substrate kinetic colorimetric method (IFCC recommended for alpha-amylase); amylase cleaves CNPG3 → releases CNP chromogen; rate of absorbance increase measured at 405nm at 37°C; ΔA/min proportional to amylase activity; result expressed as U/L or IU/L
- Reagent Format: Single reagent (SR), liquid stable, ready to use — no reconstitution or preparation required; liquid stable until expiry date when stored at 2–8°C; do not freeze; suitable for direct on-analyser loading
- Analyser Compatibility: Compatible with semi-automated bench-top colorimeters and spectrophotometers (12ml format); compatible with higher-throughput semi-automated and fully automated biochemistry analysers (60ml format); open-reagent design — not instrument-locked
- Sample Types and Interferences: Serum and heparin plasma (preferred); urine (amylase measurement); EDTA, oxalate, citrate anticoagulants inhibit amylase and must not be used; avoid haemolytic samples; serum amylase stable 1 week at 2–8°C if assay not completed immediately
Frequently asked questions
The Infinite Amylase Reagent Liquid Stable is a biochemistry reagent kit manufactured by Accurex Biomedical Pvt Ltd, Mumbai — described on the Accurex website as India's first biochemical reagent manufacturing company, with over six decades of experience in clinical chemistry diagnostics. The Infinite brand is Accurex's flagship clinical chemistry reagent range, distributed across India and export markets globally. The amylase reagent in the 12ml liquid stable format is a single ready-to-use reagent for the quantitative determination of alpha-amylase enzyme activity in serum and urine using the CNPG3 substrate kinetic method.
The 12ml single-reagent format is designed for clinical laboratories running amylase on semi-automated bench-top analysers at moderate daily volumes. In laboratories where daily amylase test numbers are limited — district hospitals, standalone diagnostic centres, and mid-tier private laboratories — opening a large-volume reagent bottle for each run exposes the reagent to repeated temperature cycling and ambient air contact, which progressively degrades activity. The 12ml format limits this by providing a volume appropriate to the actual daily test throughput, reducing wastage and improving analytical quality by ensuring the reagent in use is at peak stability throughout each run.
The Infinite Amylase Reagent uses the CNPG3 (2-chloro-4-nitrophenyl-α-D-maltotrioside) substrate kinetic colorimetric method — the approach recommended by the IFCC (International Federation of Clinical Chemistry) for clinical alpha-amylase measurement. In the assay, alpha-amylase in the patient's sample cleaves the CNPG3 synthetic substrate, producing the chromogenic product CNP (2-chloro-4-nitrophenol). The rate of increase in absorbance at 405nm, measured at 37°C over a defined time interval, is directly proportional to the amylase enzyme activity in the sample. The result is expressed in U/L or IU/L and is directly comparable across IFCC-standardised platforms.
Serum alpha-amylase rises within 2 to 12 hours of acute pancreatitis onset, peaks at 12 to 72 hours, and remains elevated for 3 to 7 days. This time-sensitive window makes amylase a key diagnostic test in the emergency evaluation of severe upper abdominal pain. Elevated serum amylase is also associated with chronic pancreatitis, biliary obstruction, salivary gland disorders, perforated peptic ulcer, renal failure (impaired amylase clearance), ectopic pregnancy, and macroamylasemia. Urine amylase, which remains elevated longer than serum amylase in pancreatitis, is also measurable with this reagent and can be useful when serum levels have already begun to normalise.
The Infinite Amylase Liquid Stable Reagent accepts serum and plasma samples. Heparin plasma is acceptable. EDTA, oxalate, and citrate anticoagulants must not be used because they chelate the divalent metal ions — particularly calcium and chloride — that are required as cofactors for amylase enzymatic activity. Using chelating anticoagulants produces falsely low amylase results that do not reflect the true enzyme activity in the patient. Serum samples should be collected without haemolysis where possible, as significant haemolysis can affect the 405nm absorbance measurement. Urine samples for amylase measurement should be fresh and well-mixed before testing.
The Infinite Amylase Liquid Stable reagent is confirmed available in a 12ml single-reagent format (for semi-automated bench-top analysers) and a 60ml format (for higher-throughput semi-automated and automated analysers). Both formats are ready to use — no reconstitution or mixing is required. Storage is at 2–8°C throughout shelf life. The reagent must not be frozen. For export and wholesale procurement, Sara Wellness supplies both volume formats and can combine amylase reagent orders with other Infinite/Accurex biochemistry parameters in a single cold-chain export shipment.
Microlisa HIV Ag & Ab 4th Generation ELISA Test Kit
Blood screening exists in a category of laboratory work where the margin for error is not just professionally unacceptable but medically catastrophic. A false negative in HIV screening does not just fail a test. It compromises patient safety, undermines transfusion protocols, and exposes healthcare systems to risks that nobody wants to calculate. Microlisa HIV Ag & Ab 4th Generation ELISA was engineered to close the detection window that makes early HIV infection so difficult to identify reliably. This is an in-vitro qualitative enzyme immunoassay designed for simultaneous detection of antibodies to HIV-1 (including Group O and subtype C prevalent in India), HIV-2, and HIV-1 p24 antigen in human serum or plasma. The test is intended for screening of blood donors, diagnostic testing of individuals at risk for HIV infection, and clinical evaluation of patients with AIDS-related symptoms. It represents the fourth generation of HIV ELISA technology, which detects both antibodies and antigens simultaneously rather than antibodies alone. The clinical advantage of 4th generation testing is the shortened window period. Traditional antibody-only tests miss early seroconversion cases where HIV-1 p24 antigen is present but antibodies have not yet developed to detectable levels. By detecting p24 antigen during the acute infection phase (typically 2 to 4 weeks post-exposure), this assay identifies infections approximately 1 to 2 weeks earlier than 3rd generation antibody-only tests. That earlier detection matters critically in blood donor screening and post-exposure monitoring. The assay is based on sandwich ELISA methodology. Microtiter wells are pre-coated with HIV envelope proteins (gp41, C-terminus of gp120 for HIV-1, and gp36 for HIV-2) and anti-p24 monoclonal antibodies. When specimens are added, any HIV antibodies or p24 antigen present bind to the coated antigens or antibodies. After washing, horseradish peroxidase (HRPO) conjugated antigens and anti-p24 antibodies are added, forming a sandwich complex. The colorimetric reaction develops proportionally to the amount of HIV antibodies or antigen present, read at 450nm absorbance. The kit uses color-coded reagents to monitor procedural steps, reducing protocol errors during multi-step workflows. Breakaway microwell strips allow testing flexibility from single specimens to full 96-well plate runs. Storage stability is maintained at 2-8°C with a shelf life of 24 months unopened. Total assay time including incubation steps is approximately 120 minutes. Sensitivity and specificity meet international standards for 4th generation HIV screening. Clinical evaluations demonstrate 100% sensitivity in detecting seroconversion panels and p24 antigen standards quantified down to 200 pg/ml. Specificity exceeds 99.5% when tested against large sample populations. The test detects all major HIV-1 subtypes including Group O and subtype C, which are epidemiologically significant in the Indian subcontinent. For distributors supplying blood banks, transfusion centers, diagnostic laboratories, and public health screening programs, Microlisa HIV Ag & Ab represents a clinically validated 4th generation screening platform with predictable reorder cycles. Sara Wellness has been exporting in-vitro diagnostic kits and laboratory reagents from India for 15 years.
Advantage PAN Malaria Card Rapid Diagnostic Test Kit
Malaria diagnosis in endemic regions operates under time pressure that microscopy cannot always accommodate. A patient presenting with fever in a rural health center at midnight does not have the luxury of waiting until morning for a trained microscopist to arrive, prepare slides, and spend twenty minutes examining blood films under oil immersion. That delay can mean the difference between timely artemisinin treatment and cerebral malaria developing overnight. Advantage PAN Malaria Card was designed to deliver species-level diagnosis in settings where microscopy is impractical or unavailable. This is a rapid visual immunoassay for qualitative detection of all four human Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) based on pan-specific plasmodium lactate dehydrogenase (pLDH) antigen in whole blood. The test provides results within 20 minutes using a simple fingerstick blood sample, no laboratory equipment required, making it ideal for point-of-care testing in primary health centers, rural clinics, field hospitals, and outbreak response settings. The assay is based on sandwich immunochromatography using monoclonal antibodies specific to pLDH, an enzyme produced by all Plasmodium species during their erythrocytic life cycle. When infected blood is added to the test device and assay buffer is applied, red blood cells lyse and pLDH antigen (if present) binds to gold-conjugated anti-pLDH antibodies. This complex migrates along the nitrocellulose membrane and is captured by immobilized anti-pLDH antibodies at the test line, producing a visible pink-purple band that confirms malaria infection. The see-through device design allows direct visualization of sample migration and result development, which helps identify invalid tests caused by insufficient sample volume or improper application. This transparency reduces the ambiguity that plagues some lateral flow devices where internal workings are hidden. Sensitivity and specificity have been validated through WHO malaria RDT evaluation programs using panels of wild and cultured parasites. The test detects parasitemia levels above 100 parasites per microliter of blood for both P. falciparum and P. vivax, which is clinically relevant for symptomatic infections requiring treatment. Specificity exceeds 99% when tested against cross-reactive conditions including dengue, leptospirosis, typhoid, and other febrile illnesses common in malaria-endemic areas. Shelf life is 24 to 30 months when stored at 4-30°C, which is critical for stockpiling in tropical climates where cold chain infrastructure is unreliable. The extended temperature stability means the test remains functional even when stored at ambient temperatures in resource-limited settings. Each kit contains individually sealed test devices, buffer vials, blood collection pipettes, and instructions for use. The test requires no special training beyond basic clinical skills and can be performed by nurses, paramedics, or trained community health workers. For distributors supplying national malaria control programs, public health departments, NGO field operations, and private diagnostic laboratories, Advantage PAN Malaria Card represents a WHO-evaluated rapid diagnostic platform with predictable consumption tied to malaria case loads. Sara Wellness has been exporting rapid diagnostic test kits and laboratory reagents from India for 15 years.
Human Serum Coombs Antisera (Antihuman Globulin Reagent)
Blood banking operates on a fundamental requirement that most people never think about until something goes wrong. Every unit of blood transfused must be confirmed compatible with the recipient's immune system. Every pregnant woman screened for antibodies that could harm her unborn child. Every suspected case of hemolytic anemia investigated for antibodies attacking the patient's own red blood cells. None of this happens without Coombs antisera making the invisible antibodies visible. Human Serum Coombs Antisera is the reagent that makes antiglobulin testing possible in blood banks and immunohematology laboratories worldwide. This is antihuman globulin (AHG) reagent used in both direct and indirect antiglobulin tests (Coombs tests) to detect antibodies and complement components bound to red blood cell surfaces or present free in serum. The reagent is produced by immunizing animals (typically rabbits) with human immunoglobulins, which induces production of polyclonal antibodies specific for human IgG antibodies and complement factor C3d. When added to washed red blood cells coated with IgG or complement, the antihuman antibodies bind to the human antibodies and form bridges between adjacent sensitized cells, causing visible agglutination. The direct antiglobulin test (DAT) detects antibodies or complement already bound to red blood cell surfaces in vivo. This test is critical for diagnosing autoimmune hemolytic anemia, investigating hemolytic transfusion reactions, and diagnosing hemolytic disease of the fetus and newborn. The indirect antiglobulin test (IAT) detects free antibodies circulating in serum or plasma. This test is essential for pre-transfusion antibody screening, crossmatching blood units for compatibility, and prenatal antibody screening in pregnant women. Polyspecific Coombs antisera (like the green-colored reagent shown) contains antibodies against both IgG and C3d complement, providing broad-spectrum detection. When the polyspecific reagent produces a positive result, monospecific antisera (anti-IgG alone or anti-C3d alone) are used for follow-up testing to characterize whether red cells are coated with IgG antibodies, complement, or both. This differentiation is clinically important because it helps determine the cause and clinical significance of the positive test. The reagent is typically dyed green using patent blue and tartrazine to allow easy visual identification during laboratory workflows where multiple reagents are used simultaneously. Storage at 2-8°C maintains reagent potency until the expiration date printed on the bottle, typically 18 to 24 months from manufacture. The reagent contains sodium azide (0.1% w/v) as a preservative, which inhibits bacterial growth but requires careful handling and disposal. Each dropper bottle delivers approximately 40 microliters per drop, allowing precise volumetric dosing during testing. The reagent must not be diluted and should not be used if turbid, as turbidity indicates bacterial contamination or protein aggregation that will compromise test performance. For distributors supplying blood banks, hospital transfusion services, reference immunohematology laboratories, and donor screening centers, Coombs antisera represents an essential reagent with consumption directly tied to transfusion volume and prenatal screening programs. Sara Wellness has been exporting immunohematology reagents and blood banking supplies from India for 15 years.